A Specific Mutation Links Some Forms of Inherited Melanoma
|
By LabMedica International staff writers Posted on 09 Apr 2014 |
![Image: Melanoma on a patient\'s skin (Photo courtesy of the [US] National Cancer Institute). Image: Melanoma on a patient\'s skin (Photo courtesy of the [US] National Cancer Institute).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2014-04-09/GMS-097.jpg)
Image: Melanoma on a patient\'s skin (Photo courtesy of the [US] National Cancer Institute).
A mutation that inactivates the POT1 (protection of telomeres 1) gene has been linked to the development of an inherited form of melanoma.
The POT1 gene encodes for synthesis of "protection of telomeres protein 1" protein, a nuclear protein involved in telomere maintenance. This protein functions as a member of a multiprotein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation.
Investigators at the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) and the University of Leeds (United Kingdom) searched for unrecognized promelanoma genes by sequencing the DNA from184 melanoma patients from 105 families recruited in the United Kingdom, The Netherlands, and Australia that were negative for variants in genes known to be linked to predisposition for developing melanoma.
They identified families where melanoma co-segregated with loss-of-function variants in the POT1gene, with a proportion of family members presenting with an early age of onset and multiple primary tumors. They showed that these variants either affected POT1 mRNA splicing or altered key residues in the highly conserved oligonucleotide/oligosaccharide-binding domains of POT1, disrupting protein-telomere binding and leading to increased telomere length. These findings suggest that POT1 variants predispose to melanoma formation via a direct effect on telomeres.
"Genomics is on the verge of transforming the healthcare system – this study highlights the potential clinical benefits that can be gained through genomic studies and offers potential strategies to improve patient care and disease management," said senior author Dr. David Adams, leader of the experimental cancer genetics program at the Wellcome Trust Sanger Institute. "With this discovery we should be able to determine who in a family is at risk, and in turn, who should be regularly screened for early detection."
The article linking POT1 mutations to melanoma was published in the March 30, 2014, online edition of the journal Nature Genetics.
Related Links:
Wellcome Trust Sanger Institute
University of Leeds
The POT1 gene encodes for synthesis of "protection of telomeres protein 1" protein, a nuclear protein involved in telomere maintenance. This protein functions as a member of a multiprotein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation.
Investigators at the Wellcome Trust Sanger Institute (Hinxton, United Kingdom) and the University of Leeds (United Kingdom) searched for unrecognized promelanoma genes by sequencing the DNA from184 melanoma patients from 105 families recruited in the United Kingdom, The Netherlands, and Australia that were negative for variants in genes known to be linked to predisposition for developing melanoma.
They identified families where melanoma co-segregated with loss-of-function variants in the POT1gene, with a proportion of family members presenting with an early age of onset and multiple primary tumors. They showed that these variants either affected POT1 mRNA splicing or altered key residues in the highly conserved oligonucleotide/oligosaccharide-binding domains of POT1, disrupting protein-telomere binding and leading to increased telomere length. These findings suggest that POT1 variants predispose to melanoma formation via a direct effect on telomeres.
"Genomics is on the verge of transforming the healthcare system – this study highlights the potential clinical benefits that can be gained through genomic studies and offers potential strategies to improve patient care and disease management," said senior author Dr. David Adams, leader of the experimental cancer genetics program at the Wellcome Trust Sanger Institute. "With this discovery we should be able to determine who in a family is at risk, and in turn, who should be regularly screened for early detection."
The article linking POT1 mutations to melanoma was published in the March 30, 2014, online edition of the journal Nature Genetics.
Related Links:
Wellcome Trust Sanger Institute
University of Leeds
Latest Pathology News
- Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
- New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
- AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
- High-Resolution Cancer Virus Imaging Uncovers Potential Therapeutic Targets
- Research Consortium Harnesses AI and Spatial Biology to Advance Cancer Discovery
- AI Tool Helps See How Cells Work Together Inside Diseased Tissue
- AI-Powered Microscope Diagnoses Malaria in Blood Smears Within Minutes
- Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
- First-Of-Its-Kind Test Identifies Autism Risk at Birth
- AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
- Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
- Fast Label-Free Method Identifies Aggressive Cancer Cells
- New X-Ray Method Promises Advances in Histology
- Single-Cell Profiling Technique Could Guide Early Cancer Detection
- Intraoperative Tumor Histology to Improve Cancer Surgeries
- Rapid Stool Test Could Help Pinpoint IBD Diagnosis
Channels
Clinical Chemistry
view channel
Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Counterfeit and substandard medicines remain a serious global health threat, with World Health Organization estimates suggesting that 10.5% of medicines in low- and middle-income countries are either fake... Read more
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







